Abstract
Background and Objective: Thyroid-associated ophthalmopathy (TAO) is the most common extrathyroidal manifestation of Graves disease, occasionally severe and refractory to treatment, mainly in long-term disease. In these cases, one of the most important infiltrating cytokines in the orbital tissue is interleukin-6 (IL-6).
Methods: This is a case report, the methodology consisted of the application of tocilizumab in a patient with graves disease and the patient's follow-up.
Results: We present the case of a 54-year-old male with TAO who responded adequately to treatment with tocilizumab, an antibody directed against the IL-6 receptor.
Conclusion: Tocilizumab could be an optional treatment in patients with TAO.
Keywords: Thyroid-associated ophthalmopathy, Graves` associated ophthalmopathy, tocilizumab, IL-6, extrathyroidal manifestation, infiltrating cytokines.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Successful Treatment for Severe Thyroid-associated Ophthalmopathy with Tocilizumab
Volume: 18 Issue: 6
Author(s): Carlos A. Canas*, Fabio Bonilla-Abadia, Katherine Vallejo, Hector M. Rengifo, Marco A. Gallon and Gabriel J. Tobon
Affiliation:
- GIRAT: Grupo de investigacion en Reumatologia, Autoinmunidad y Medicina Traslacional, Fundacion Valle del Lili and Universidad Icesi, Cali,Colombia
Keywords: Thyroid-associated ophthalmopathy, Graves` associated ophthalmopathy, tocilizumab, IL-6, extrathyroidal manifestation, infiltrating cytokines.
Abstract: Background and Objective: Thyroid-associated ophthalmopathy (TAO) is the most common extrathyroidal manifestation of Graves disease, occasionally severe and refractory to treatment, mainly in long-term disease. In these cases, one of the most important infiltrating cytokines in the orbital tissue is interleukin-6 (IL-6).
Methods: This is a case report, the methodology consisted of the application of tocilizumab in a patient with graves disease and the patient's follow-up.
Results: We present the case of a 54-year-old male with TAO who responded adequately to treatment with tocilizumab, an antibody directed against the IL-6 receptor.
Conclusion: Tocilizumab could be an optional treatment in patients with TAO.
Export Options
About this article
Cite this article as:
Canas A. Carlos *, Bonilla-Abadia Fabio , Vallejo Katherine , Rengifo M. Hector , Gallon A. Marco and Tobon J. Gabriel , Successful Treatment for Severe Thyroid-associated Ophthalmopathy with Tocilizumab, Endocrine, Metabolic & Immune Disorders - Drug Targets 2018; 18 (6) . https://dx.doi.org/10.2174/1871530318666180702150243
DOI https://dx.doi.org/10.2174/1871530318666180702150243 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mitochondria in Cancer Stem Cells: A Target for Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Lymphocytes in Alzheimer’s Disease Pathology: Altered Signaling Pathways
Current Alzheimer Research Bisphosphonate Therapy for Patients with Breast Cancer
Current Cancer Therapy Reviews Tyrosine Kinases as Targets for Anti-Inflammatory Therapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Synthetic Aziridines in Medicinal Chemistry: A Mini-Review
Mini-Reviews in Medicinal Chemistry Anticancer Drugs Targeting the Apoptotic Pathway
Medicinal Chemistry Reviews - Online (Discontinued) Arylurea Derivatives: A Class of Potential Cancer Targeting Agents
Current Topics in Medicinal Chemistry Novel Pharmacodynamic Approach to Assess Obatoclax (GX15-070) and Bortezomib (BTZ) Synergism in Non-Hodgkin’s Lymphoma
Clinical Cancer Drugs Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery Towards Improved Therapies Using Nanopharmaceuticals: Recent Patents on Pharmaceutical Nanoformulations
Recent Patents on Food, Nutrition & Agriculture Targeting Signaling Pathways in Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Targeting the Nucleotide Metabolism Proteins of the NUDIX Family and SAMHD1 in Cancer
Current Medicinal Chemistry PiWi RNA in Neurodevelopment and Neurodegenerative Disorders
Current Molecular Pharmacology Histone Lysine-Specific Methyltransferases and Demethylases in Carcinogenesis: New Targets for Cancer Therapy and Prevention
Current Cancer Drug Targets Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Current Cancer Drug Targets Antibody-Dependent Cell-Mediated Cytotoxicity Through Natural Killer (NK) Cells: Unlocking NK Cells for Future Immunotherapy
Current Pharmaceutical Biotechnology GPR55, a Lysophosphatidylinositol Receptor with Cannabinoid Sensitivity?
Current Topics in Medicinal Chemistry Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins
Recent Patents on Anti-Cancer Drug Discovery Alkylphospholipids are Signal Transduction Modulators with Potential for Anticancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies
Current Cancer Drug Targets